Averting inflammation by targeting the cytokine environment

  title={Averting inflammation by targeting the cytokine environment},
  author={Manfred Kopf and Martin F. Bachmann and Benjamin J. Marsland},
  journal={Nature Reviews Drug Discovery},
Cytokines are key instigators and regulators of immune responses and therefore hold great potential as targets for new therapeutic strategies. However, the selection of which cytokines to target, and in particular the identification of which cytokines regulate the rate-limiting steps of disease pathways, is crucial to the success of such strategies. Moreover, balancing the need for ablating pathological inflammatory responses and simultaneously maintaining the ability to control infectious… 
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.
This review focuses on four inflammatory cytokines--tumor necrosis factor α (TNFα), interleukin-6 (IL-6), IL-6, IL-23 and IL-17--and dissect how the dysregulation of these cytokines regulates autoimmune diseases.
Biology of IL‐2 and its therapeutic modulation: Mechanisms and strategies
The underlying basic science related to IL‐2 and its biologic actions are reviewed, the current state ofIL‐2‐based immunotherapy is discussed, and emerging concepts of modulating the activities of this cytokine are focused on, including the generation of novel partial cytokine agonists as new potential therapeutics.
Emerging cytokine networks in colorectal cancer
How cancer mutations and epigenetic adaptations influence the oncogenic potential of cytokines is discussed, a relatively unexplored area that could yield crucial insights into tumour immunology and facilitate the effective application of cytokine-modulatory therapies for CRC.
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
It is explored how gp130 signaling controls disease progression and why IL-6 has a special role among these cytokines as an inflammatory regulator in autoimmunity, inflammation, and cancer.
Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages
These findings identify SIKs as a key molecular switch whose inhibition reprograms macrophages to an anti-inflammatory phenotype and suggest that drugs that target these protein kinases may have therapeutic potential for the treatment of inflammatory and autoimmune diseases.
Novel Immunomodulatory Therapies for Respiratory Pathologies


Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis1
This study combines genetic approaches and intervention strategies to describe a fundamental requirement for IL-6-mediated STAT3 signaling in orchestrating the inflammatory infiltrate in monoarticular and systemic models of experimental arthritis, and suggests that selective inhibition ofIL-6 trans signaling may provide a more refined intervention strategy for blocking IL- 6-driven proarthritic activities.
Cytokine-mediated regulation of antimicrobial proteins
New evidence shows that the production of certain antimicrobial proteins by epithelial cells can also be regulated by cytokines of the innate and adaptive immune systems, suggesting that this T-cell lineage and its cytokines have important roles in skin and mucosal immunity.
What makes a good anti-inflammatory drug target?
IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia
Although both cytokines regulated CXC chemokines and granulocyte colony–stimulating factor production in the lung, only IL-22 increased lung epithelial cell proliferation and increased transepithelial resistance to injury, and data support the concept that the TH17 cell lineage and its effector molecules have evolved to effect host defense against extracellular pathogens at mucosal sites.
Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa
Recent progress is summarized in understanding of the function of IL-17-producing cells as a bridge between innate and adaptive immunity against infectious diseases at the mucosa.
Colony-stimulating factors in inflammation and autoimmunity
The distinct biological features of CSFs offer opportunities for specific targeting, but with some associated risks, are described and the probable specific outcomes of targeting CSFs in vivo are discussed.
IL-17 family cytokines and the expanding diversity of effector T cell lineages.
The factors that specify differentiation of a new effector T cell lineage-Th17-have now been identified, providing a new arm of adaptive immunity and presenting a unifying model that can explain many heretofore confusing aspects of immune regulation, immune pathogenesis, and host defense.
Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract
A dual function is identified for IL-25: first, in promoting type 2 cytokine-dependent immunity to gastrointestinal helminth infection and, second, in limiting proinflammatory cytokine production and chronic intestinal inflammation.